Results 141 to 150 of about 1,243,120 (289)

Patritumab deruxtecan in breast cancer treatment: a drug evaluation. [PDF]

Future Oncol
Sabau A, Paparo J, Cheikh-Hussin R, Corcos N, Mosele F, Pistilli B.   +5 more
europepmc   +1 more source

Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation. [PDF]

Front Pharmacol, 2022
Xiao RR, Jin L, Xie N, Luo P, Gao W, Tu P, Ai X.   +6 more
europepmc   +1 more source

PHARMACOGNOSTIC EVALUATION OF GLYCYRRHIZA GLABRA LINN (YASHTIMADHU) FROM RAW DRUG MARKETS OF KERALA.

, 2018
S IndhuB
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

Blood Advances, 2018
E. Dianne Pulte, Lei Nie, Nicole Gormley, Kirsten B. Goldberg, Amy McKee, Ann Farrell, Richard Pazdur   +6 more
doaj   +1 more source

The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study. [PDF]

J Pharm Policy Pract
Algabbani AM, Hafiz R, AlWon B.
europepmc   +1 more source

Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation. [PDF]

Chin J Cancer Res, 2022
Zou L, Qi Y, Tang L, Du Y, Xiang M, Chen X, Ma J, Yang Z.   +7 more
europepmc   +1 more source

Evaluation of dose of unstable drug administered by infusion.

, 1990
Takashi Mizuma, Sayuri Nakajima, Hiroshi Takase, Michiyo Komori, Teruaki Nakagawa, Isamu Horikoshi   +5 more
openalex   +2 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. [PDF]

Cells
Chen M, Zhang T, Yang S, Niu Y, Ge Y, Chen Z, Zhang J, Pu Y, Gu Z, Liang G.   +9 more
europepmc   +1 more source